Skip to main content
SpringerLink
Log in

Therapeutic Targeting of the Lymphovascular System in Cancer: Promise and Challenge

  • Chapter
  • First Online:
From Local Invasion to Metastatic Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 919 Accesses

Abstract

Acquisition of the metastatic phenotype by cells within a solid tumor initiates a sequence of events that represent, for most cancer patients, the primary cause of morbidity and mortality of this disease. This realization gave birth to a field of research focused on unraveling the nature of the metastatic process and led to many groundbreaking scientific achievements. However, it has proven extremely difficult to translate these discoveries into efficacious treatments that target the metastatic process. While hematogenous dissemination of tumor cells through blood vessels is well understood, the contribution of lymphatic metastasis to the overall metastatic process is more controversial. We attempt to define the common ground that must be achieved by basic scientists, translational researchers, and clinicians before targeting of lymphatic metastasis can be attempted in the clinic. To better illustrate the key issues involved in this debate, we examine the controversies related to tumor dissemination through lymphatic vessels from two distinct points of view. First, we review the clinical data regarding invasive melanoma, a tumor with propensity for lymphatic metastasis as the initial route of metastasis. Second, we examine how the uncertainty regarding the clinical relevance of lymphatic metastasis affects the plans for clinical development of antibody antagonists of the vascular endothelial growth factor receptor-3 (VEGFR-3), an important mediator of tumor lymphangiogenesis. Our goal is to provide a framework for ongoing dialog in the field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127(4): 679–695.

    Article  PubMed  CAS  Google Scholar 

  2. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6(6):449–458.

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22: 339–347.

    PubMed  CAS  Google Scholar 

  4. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22(20):3172–3179.

    Article  PubMed  CAS  Google Scholar 

  5. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002; 62(5):1315–1320.

    PubMed  CAS  Google Scholar 

  6. Kato T, Prevo R, Steers G, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer 2005; 93(10):1168–1174.

    Article  PubMed  CAS  Google Scholar 

  7. Zeng Y, Opeskin K, Baldwin ME, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004; 10(15):5137–5144.

    Article  PubMed  CAS  Google Scholar 

  8. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16(6):2253–2260.

    PubMed  CAS  Google Scholar 

  9. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg 2005; 42(7):460–534.

    Article  PubMed  Google Scholar 

  10. Leong SP. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 2004; 11(3 Suppl): 192S–197S.

    PubMed  Google Scholar 

  11. Eccles S, Paon L, Sleeman J. Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 2007; 24(8):619–636.

    Google Scholar 

  12. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12(8): 895–904.

    Article  PubMed  CAS  Google Scholar 

  13. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438(7070): 946–953.

    Article  PubMed  CAS  Google Scholar 

  14. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2(8):573–583.

    Article  PubMed  CAS  Google Scholar 

  15. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7(11): 834–846.

    Article  PubMed  CAS  Google Scholar 

  16. Paietta E. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept? Bone Marrow Transplant 2002; 29(6): 459–465.

    Article  PubMed  CAS  Google Scholar 

  17. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106(7):1431–1442.

    Article  PubMed  CAS  Google Scholar 

  18. Morton DL. Sentinel node mapping and an International Sentinel Node Society: current issues and future directions. Ann Surg Oncol 2004; 11(3 Suppl):137S–143S.

    PubMed  Google Scholar 

  19. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992; 127(4):392–399.

    Article  PubMed  CAS  Google Scholar 

  20. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17(3):976–983.

    PubMed  CAS  Google Scholar 

  21. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355(13):1307–1317.

    Article  PubMed  CAS  Google Scholar 

  22. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst 2001; 93(2): 96–111.

    Article  PubMed  CAS  Google Scholar 

  23. Starritt EC, Joseph D, McKinnon JG, Lo SK, de Wilt JH, Thompson JF. Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg 2004; 240(5):866–874.

    Article  PubMed  Google Scholar 

  24. Gershenwald JE, Ross MI. Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol 2007; 4(5):278–279.

    Article  PubMed  Google Scholar 

  25. Morton DL, Thompson JF, Cochran AJ. Sentinel-node biopsy in melanoma, author reply. N Engl J Med 2007; 356: 419–421.

    CAS  Google Scholar 

  26. Cox C, White L, Allred N, et al. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol 2006; 13(5):708–711.

    Article  PubMed  Google Scholar 

  27. Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005; 91(1):11–18.

    Article  PubMed  Google Scholar 

  28. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222(3):394–399.

    Article  PubMed  CAS  Google Scholar 

  29. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220(3):391–398.

    Article  PubMed  CAS  Google Scholar 

  30. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006; 7(12): 983–990.

    Article  PubMed  Google Scholar 

  31. Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer 2006; 94(10):1355–1360.

    Article  PubMed  CAS  Google Scholar 

  32. Nisato RE, Tille JC, Pepper MS. Lymphangiogenesis and tumor metastasis. Thromb Haemost 2003; 90(4):591–597.

    PubMed  CAS  Google Scholar 

  33. Shields JD, Borsetti M, Rigby H, et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004; 90(3):693–700.

    Article  PubMed  CAS  Google Scholar 

  34. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8(6): 464–478.

    Article  PubMed  CAS  Google Scholar 

  35. Wissmann C, Detmar M. Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 2006; 12(23): 6865–6868.

    Article  PubMed  CAS  Google Scholar 

  36. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7(2):199–205.

    Article  PubMed  CAS  Google Scholar 

  37. He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005; 65(11):4739–4746.

    Article  PubMed  CAS  Google Scholar 

  38. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005; 97(1):14–21.

    Article  PubMed  CAS  Google Scholar 

  39. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 2004; 10(8):813–815.

    Article  PubMed  CAS  Google Scholar 

  40. Baluk P, Tammela T, Ator E, et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005; 115(2):247–257.

    PubMed  CAS  Google Scholar 

  41. Angeli V, Ginhoux F, Llodra J, et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006; 24(2): 203–215.

    Article  PubMed  CAS  Google Scholar 

  42. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006; 66(5):2650–2657.

    Article  PubMed  CAS  Google Scholar 

  43. Hoshida T, Isaka N, Hagendoorn J, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006; 66(16):8065–8075.

    Article  PubMed  CAS  Google Scholar 

  44. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154(5):1381–1390.

    Article  PubMed  CAS  Google Scholar 

  45. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood. 2007; 109(3):1010–1017.

    Google Scholar 

  46. Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K, Wu L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008; 68(19):7828–7837.

    Google Scholar 

  47. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201(7):1089–1099.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

B.P. would like to thank Dr. Larry Witte (ImClone Systems) whose support was instrumental to the production of the antagonist antibodies to VEGFR-3.

Author information

Authors and Affiliations

  1. Department of Cell Biology, ImClone Systems Incorporated, New York, NY, USA

    Bronislaw Pytowski PhD

  2. Department of Surgical Oncology and Cancer Biology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA

    Jeffrey E. Gershenwald MD, FACS

Authors
  1. Bronislaw Pytowski PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey E. Gershenwald MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, University of California, San Francisco, Divisadero St. 1600, San Francisco, 94115, USA

    Stanley P. L. Leong

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pytowski, B., Gershenwald, J.E. (2009). Therapeutic Targeting of the Lymphovascular System in Cancer: Promise and Challenge. In: Leong, S. (eds) From Local Invasion to Metastatic Cancer. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-087-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-087-8_17

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-086-1

  • Online ISBN: 978-1-60327-087-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation